Invesco
MLYS icon

Invesco’s Mineralys Therapeutics MLYS Stock Holding History

Invesco’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
42,311
+13,170
+45% +$386K ﹤0.01% 2803
2025
Q4 		$1.06M Sell
29,141
-158,845
-84% -$6.37M ﹤0.01% 2885
2025
Q3 		$7.13M Buy
187,986
+162,243
+630% +$3.51M ﹤0.01% 2039
2025
Q2 		$348K Sell
25,743
-282,567
-92% -$4.09M ﹤0.01% 3312
2025
Q1 		$4.9M Buy
+308,310
New +$3.55M ﹤0.01% 2161

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Invesco's MLYS Position: Q1 2026 in Review

Invesco increased its Mineralys Therapeutics (MLYS) stake by 45% in Q1 2026, buying an estimated $386K and bringing the position to 42,311 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

Invesco first reported a position in MLYS in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.13M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Invesco held 42,311 shares of Mineralys Therapeutics worth $1.15M as of Q1 2026.
  • Invesco bought 13,170 Mineralys Therapeutics shares in Q1 2026, an estimated $386K.
  • Mineralys Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2803 holding.
  • Invesco first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Invesco's Mineralys Therapeutics position peaked at $7.13M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.